El Issaoui Meryam, Elissaoui Sophia, Elmelund Marlene, Klarskov Niels
Department of Obstetrics and Gynecology, Herlev and Gentofte University Hospital, Borgmester Ib Juuls Vej 1, 16. Etage, 2730, Herlev, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Int Urogynecol J. 2025 Jan;36(1):107-115. doi: 10.1007/s00192-024-05960-8. Epub 2024 Nov 7.
We aimed to evaluate the clean intermittent catheterization (CIC) rate in women undergoing their first OnabotulinumtoxinA (BTX-A) treatment and to investigate factors predictive of initiating CIC.
This was a retrospective cohort of women, who had their first BTX-A treatment for symptoms of overactive bladder (OAB) syndrome, with a pretreatment urodynamic study (UDS). We reviewed demographic, medical and gynecological history, UDS, pretreatment bladder diaries, objective examinations, BTX-A treatment details, and post-void residual (PVR) reports in the electronic medical record. Botox® Allergan 100 International Units were injected into the detrusor at 10-20 sites. Statistical analyses included univariate and multivariate logistic regression analyses.
We included 397 women. Median age was 68 (Q1-Q3: 54-76) years. CIC rate was 8.6% (n = 34) following the first BTX-A treatment. Urgency urinary incontinence (UUI) reduced the risk of undergoing CIC (OR 0.30, 95% CI 0.09-0.97). A bladder capacity of 500 ml or greater in the bladder diary increased the risk of CIC (OR 2.46, 95% CI 1.06-5.70), whereas reported leakages were associated with a decreased risk of CIC (OR 0.24, 95% CI 0.10-0.57). Multivariate logistic regression analysis showed that anterior colporrhaphy (OR 3.71, 95% CI 1.52-9.06) and 10-ml increments in median maximum cystometric capacity (OR 1.03, 95% CI 1.00-1.06) predicted CIC, whereas UUI was a protective factor for CIC (OR 0.23, 95% CI 0.07-0.79).
A history of anterior colporrhaphy, large bladder capacity, and absence of incontinence episodes in bladder diary or UDS were risk factors for CIC after the first BTX-A treatment.
我们旨在评估首次接受A型肉毒毒素(BTX-A)治疗的女性患者的清洁间歇性导尿(CIC)率,并研究预测开始CIC的因素。
这是一项回顾性队列研究,纳入了因膀胱过度活动症(OAB)综合征症状首次接受BTX-A治疗且治疗前进行了尿动力学研究(UDS)的女性患者。我们在电子病历中回顾了人口统计学、医学和妇科病史、UDS、治疗前膀胱日记、客观检查、BTX-A治疗细节以及排尿后残余尿量(PVR)报告。将100国际单位的保妥适®注射到逼尿肌的10 - 20个部位。统计分析包括单因素和多因素逻辑回归分析。
我们纳入了397名女性患者。中位年龄为68岁(四分位数间距:54 - 76岁)。首次BTX-A治疗后CIC率为8.6%(n = 34)。急迫性尿失禁(UUI)降低了接受CIC的风险(比值比[OR] 0.30,95%置信区间[CI] 0.09 - 0.97)。膀胱日记中膀胱容量为500毫升或更大增加了CIC的风险(OR 2.46,95% CI 1.06 - 5.70),而报告的漏尿与CIC风险降低相关(OR 0.24,95% CI 0.10 - 0.57)。多因素逻辑回归分析显示,前壁膨出(OR 3.71,95% CI 1.52 - 9.06)以及最大膀胱测压容量中位数每增加10毫升(OR 1.03,95% CI 1.00 - 1.06)可预测CIC,而UUI是CIC的保护因素(OR 0.23,95% CI 0.07 - 0.79)。
前壁膨出病史、膀胱容量大以及膀胱日记或UDS中无尿失禁发作是首次BTX-A治疗后CIC的危险因素。